Company Overview
About Rosebud Biosciences
Rosebud Biosciences is a San Carlos-based drug discovery company that accelerates therapeutic development for rare diseases by screening drug candidates against patient-derived organoids — miniature 3D organ models grown from patients' own cells with matching genetic mutations — using robotic automation and machine learning to identify compounds that correct disease phenotypes at a scale impossible with traditional cell line testing. Founded in 2020 and backed by Y Combinator, NSF, and other investors with $440,000 in revenue, Rosebud has achieved Stanford-validated research breakthroughs published in prestigious scientific journals, including discovering a novel drug target for pediatric heart disease.
Business Model & Competitive Advantage
Rosebud's platform addresses a fundamental problem in rare disease drug development: most rare diseases affect small patient populations (under 200,000 patients in the US), making it economically and logistically difficult to run large clinical trials. Patient-derived organoids — grown from patient biopsy or iPSC (induced pluripotent stem cell) material — provide a laboratory model that matches the actual genetic architecture of individual patients' disease, enabling more predictive pre-clinical screening than generic cell lines. Rosebud's automation infrastructure creates organoids at scale and screens therapeutic libraries against them.
Competitive Landscape 2025–2026
In 2025, Rosebud Biosciences competes in the patient-derived model drug discovery and rare disease platform market with Hubrecht Organoid Technology (HUB, a leading organoid CRO), Champions Oncology (patient-derived xenograft testing), and academic rare disease organoid programs for patient-derived drug screening services. The organoid technology field has matured significantly — Nature has published multiple studies validating organoid drug response prediction. The rare disease focus is strategically important: FDA Orphan Drug Designation, breakthrough therapy pathways, and smaller patient recruitment requirements make rare disease a more capital-efficient development path for preclinical-stage companies. The 2025 strategy focuses on building the organoid disease model library for key rare disease indications, establishing CRO (contract research organization) services for pharma partners, and advancing internal therapeutic programs from the computational hits identified in organoid screening.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Rosebud Biosciences is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Campfire
Campfire is a United States-based AI-native enterprise resource planning (ERP) company — backed by Y Combinator (S23) with $38.5 million raised including a $35 million Series A led by Accel in June 20
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Bucket Robotics
Bucket Robotics is an autonomous mobile robot (AMR) company that designs modular, rapidly deployable robots for warehouse automation and industrial material handling. Unlike traditional warehouse auto
Armilla AI
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act
Compare Rosebud Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Rosebud Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Rosebud Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Rosebud Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →